Objective Assess association between adherence and persistence with second-generation oral antipsychotics (SGOAs), psychiatric-related relapse and healthcare utilization among patients with schizophrenia experiencing two or more psychiatric-related relapses. Methods A retrospective analysis of the US Medicaid Multi-State Database for [2004][2005][2006][2007][2008]. Patients with schizophrenia (aged 18-64) with two or more psychiatric-related relapses within 1 year after SGOA initiation were selected. Associations between a dichotomous measure of adherence and persistence with SGOAs and psychiatric-related relapse and healthcare utilization were assessed using unadjusted and covariate-adjusted regression models. No adjustment was made for multiplicity. Key findings Study cohort consisted of 3714 patients with mean age of 42.6 years. Overall, 45% of patients were adherent and 50% persistent with SGOAs. Unadjusted and covariate-adjusted analysis results suggested the 12-month psychiatric-related relapse rate was lower among adherent/persistent patients versus non-adherent patients (unadjusted mean: 3.85 versus 4.13; P < 0.001; covariate-adjusted incident rate ratio (IRR): 0.90; 95% confidence interval (CI): 0.86-0.94) and non-persistent patients (unadjusted mean: 3.81 versus 4.21; P < 0.001; covariate-adjusted IRR: 0.88; 95%CI: 0.84-0.92). Compared with non-persistent patients, persistent patients had significantly lower rates of all-cause inpatient admissions (IRR: 0.87; 95%CI: 0.82-0.93) and emergency department visits (IRR: 0.78; 95%CI: 0.73-0.85). Conclusions Although SGOAs have proven efficacy in lowering the rate of psychiatricrelated relapses, lower adherence and persistence rates may be an inhibiting factor in achieving optimal benefits from SGOAs. Future research is needed to assess whether newer antipsychotics with less-frequent dosing may improve adherence among patients with schizophrenia.
Introduction
Schizophrenia is a complex chronic psychiatric disorder characterized by psychosis, hallucinations, delusions, disorganized speech and behaviour, cognitive deficits, reduced emotional expression and social withdrawal. Patients with schizophrenia typically require lifelong antipsychotic use for disease management and relapse control. However, compared with earlier-developed conventional antipsychotics, second-generation oral antipsychotics (SGOAs) are the preferred choice of physicians in the management of schizophrenia, mainly because of the lower rate of extrapyramidal adverse events (AEs). Several clinical trials have effectively established the efficacy of SGOAs for maintenance treatment of schizophrenia. [1] [2] [3] [4] For chronic conditions, like schizophrenia, that require lifelong medication use, adherence is an important factor in achieving benefits of the prescribed therapy. [5, 6] Recent survey findings indicated that physicians observed medication adherence rates of 51-70% in their practices. [7] Non-adherence to the prescribed antipsychotic therapy is associated with increased risk of relapse, [8] [9] [10] greater healthcare utilization [11, 12] and higher costs. [13] [14] [15] A study by Weiden and Olfson [10] reported that non-adherence to antipsychotic therapy accounted for approximately 40% of re-hospitalizations among patients with schizophrenia. [10] Similarly, a recent literature review of inpatient costs related to antipsychotic non-adherence in the USA estimated that re-hospitalizations costs associated with antipsychotic non-adherence were US$1.48 billion (range, US$1.39-1.83 billion) in 2005. [14] In addition to adherence, persistence with the prescribed medication, which is defined as 'the duration of time from initiation to discontinuation of therapy' is considered an important factor in managing chronic conditions like schizophrenia. [5, 16] Several studies have compared persistence with various individual conventional and atypical antipsychotic medications among patients with schizophrenia. [17] [18] [19] [20] For example, a study evaluating persistence with conventional and atypical antipsychotic therapy among patients with schizophrenia who are enrolled in the US Medicaid health services programme reported that 58% of patients initiating conventional antipsychotic agent discontinued the medication compared with 33% for patients initiating atypical antipsychotics. [20] Even though studies have assessed persistence with antipsychotic therapy, limited data exist assessing the impact of non-persistence on the healthcare utilization and costs among patients with schizophrenia. A study conducted by Weiden et al. reported that lower rates of antipsychotic therapy persistence were associated with higher rates of psychiatric-related hospitalization. [9] Although studies evaluated the association between antipsychotic therapy adherence, persistence, healthcare utilization and costs, to the best of the authors' knowledge no studies have assessed this association among patients experiencing multiple psychiatric-related relapses while receiving SGOAs. Prior research suggests that patients with schizophrenia experiencing a psychiatric-related relapse event are significantly more likely to experience a second event with the first event being the most significant predictor of the second relapse event. [13] Moreover, patients experiencing multiple psychiatric-related relapses incur five times higher healthcare costs than patients without relapse. [12] Understanding the association between adherence to and persistence with SGOAs and healthcare utilization among patients with multiple relapse events is important. With the objective of addressing the current literature gap, our study examined the association between adherence to and persistence with SGOAs, psychiatric-related relapses and healthcare utilization among Medicaid-enrolled patients with schizophrenia. Since Medicaid serves as the largest payer for mental-health care in the USA, we limited our study to Medicaid-enrolled patients with schizophrenia. [21] 
Methods

Data source and patient selection
We conducted a retrospective longitudinal analysis of the Thomson Reuters' MarketScan Medicaid Multi-State Database for [2004] [2005] [2006] [2007] [2008] . Data for >26 million Medicaid enrollees from 11 states are represented in this database; for confidentiality purposes, names of states are not reported.
The data include medical and pharmacy (excluding drugs provided in an inpatient setting) utilization records and enrolment and demographic (e.g. age, race, gender) information for Medicaid enrollees A unique, encrypted identification number was available for each enrollee, enabling the longitudinal tracking of individuals' healthcare utilization and costs over time. All elements included in these data are in accordance with the US Health Insurance Portability and Accountability Act definition for limited-use datasets. [22] The institutional review board at RTI International, New Carolina, USA, approved the conduct of this study.
We initially selected adults (Ն18 years of age) with Ն1 claim for any SGOA during 1 January 2005 to 31 December 2007. The date corresponding to the first evidence of SGOA prescription claim defined the 'index SGOA date.' The index SGOA date served as the reference date to define the 'preindex' (i.e. 12-month period before the index SGOA date) and 'postindex' date periods (i.e. 12-month period on or after the index SGOA date). All patients were required to have Ն2 schizophrenia diagnoses (International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code 295.xx) in the medical records during the preindex date period. Moreover, patients were required to have Ն2 psychiatric relapse events during the postindex period. Patients with an inpatient admission or emergency department (ED) visit for psychiatric conditions (ICD-9-CM codes available upon request) were defined as having a psychiatric-related relapse event. Patients were required to have continuous Medicaid enrolment during the study periods. Finally, patients' Ն65 years old at any point during the observation period or patients with dual coverage (i.e. both Medicaid and Medicare) were excluded.
Adherence and persistence with second-generation oral antipsychotics Adherence to SGOAs
Postindex period adherence to SGOAs was measured using the adherence measure medication possession ratio (MPR), defined as: Because the data did not provide details on inpatient drug use, the number of days a patient was hospitalized during the postindex date period was subtracted from the denominator, assuming that patients received, and took as prescribed, their SGOA during hospitalization.
Persistence with SGOAs
Persistence with SGOAs was evaluated by documenting the distribution of patients who had Ն1 therapy interruption (i.e. refill gap of Ն60 days) with subsequent re-initiation, or discontinuation of therapy without subsequent re-initiation, or continuous use during the postindex date period. [23] Three categories were used to describe persistence: category 1: therapy interruption (a refill gap of Ն60 days, with subsequent re-initiation); category 2: therapy discontinuation (without subsequent SGOA re-initiation); category 3: continuous use (remaining on the index SGOA or switching to a different SGOA within the permissible gap of <60 days).
Study outcomes
The primary outcomes assessed included overall (all-cause), schizophrenia-related healthcare utilization, and psychiatric-related relapses during the postindex date period. To identify schizophrenia-related medical and pharmacy utilization, medical claims with a schizophrenia diagnosis and pharmacy claims for first-or second-generation antipsychotics were used. All-cause and schizophrenia-related healthcare utilizations were reported for the following categories: (1) the percentage of patients with Ն1 claim for the selected categories of service; (2) the number of unique inpatient and ED admissions; and (3) the number of physician office, outpatient and other ancillary care visits and pharmacy claims.
Finally, we documented the number of psychiatric-related relapses during the postindex date period.
Covariates
The primary independent variables for this study included binary indicators for SGOA adherence and persistence. Using a previously validated adherence threshold value (i.e. 80%), we classified patients in to 'non-adherent' (MPR < 0.80) and 'adherent' (MPR Ն 0.80) categories. [24] A dichotomous measure of persistence was also created; patients with SGOA interruption or discontinuation were categorized as 'nonpersistent' and patients with continuous SGOA use were categorized as 'persistent.' Other covariates considered for this analysis include age, gender, race/ethnicity health plan type, basis of Medicaid eligibility, mental-health substance abuse coverage, dose escalation, polypharmacy and comorbidity burden assessed using the Charlson Comorbidity Index score. [25, 26] 
Statistical analysis
All statistical analyses were conducted using SAS (version 9.1.3) statistical software package (SAS Institute Inc., Cary, North Carolina, USA). All analyses were stratified by adherence and persistence status. Descriptive statistics were generated, including frequencies for categorical variables and mean values and standard deviations (SDs) for continuous variables. Both unadjusted univariate and covariate-adjusted multivariable analyses were conducted to assess differences in outcomes by adherence and persistence status. Univariate analyses included assessing differences in baseline demographic characteristics and outcome measures, including allcause and schizophrenia-related healthcare utilization and psychiatric-related relapses using Student t-test (for continuous variables) and the chi-squared or Fisher exact test (for categorical variables).
Multivariable regression analyses were performed to assess differences in all-cause and schizophrenia-related healthcare utilization and psychiatric-related relapses between the adherent and persistent groups, after adjusting for demographic characteristics and baseline comorbidity burden. Two separate multivariable regression models were estimated for each outcome measure, one with a binary indicator for adherence and another with a binary indicator for persistence. Multivariable negative binomial and Poisson regression analyses were performed for outcomes categorized as count data (e.g. number of psychiatric-related relapses). For all count outcome measures, negative binomial regression models were ultimately deemed a better fit based on goodness-of-fit tests (assessed using Pearson chi-squared statistic) conducted for each model estimated. Incident rate ratios (IRRs) were obtained by exponentiating the coefficients from each model estimated. The magnitude of IRRs describes the rate of utilization between adherent (or persistent) patients versus non-adherent (or non-persistent) patients.
For each dichotomous outcome measure, a logistic regression model was estimated. Odds ratios (ORs) were obtained by exponentiating the coefficients from each logistic regression model estimated. Odds ratios illustrate the increased or decreased likelihood of event in adherent (or persistent) versus non-adherent (or non-persistent) patients. No adjustment was made for multiplicity.
Results
The final study sample consisted of 3714 patients who met all study inclusion and exclusion criteria. Table 1 presents a descriptive summary of adherence to and persistence with SGOAs during the postindex date period. The mean (standard deviation (SD)) medication possession ratio (MPR) of the study cohort was 0.66 (0.30). Approxi- Table 1 Adherence to and persistence with second-generation oral antipsychotic therapy among US Medicaid-enrolled patients with schizophrenia
Therapy adherence and persistence with second-generation oral antipsychotics
Characteristics
All patients
Total sample size, n (%) 3714 (100.00) Adherence respectively. Approximately 50% of schizophrenia patients were persistent with SGOAs. Among patients non-persistent with SGOAs, 23% had Ն1 therapy interruption of Ն60 days, whereas 27% discontinued SGOAs without subsequent re-initiation. Table 2 presents descriptive statistics on various baseline demographic characteristics of the study sample, both overall and by SGOA adherence and persistence status. The mean age of the study cohort was 42.62 (11.63) years, with adherent (43.44 (12.11) years) and persistent (43.50 (11.84) years) patients being significantly older than non-adherent (41.94 (11.19) years; P < 0.001) and nonpersistent (41.74 (11.36) years; P < 0.001) patients. Approximately 56% of the population was female. African Americans accounted for over 48% of the study cohort and were significantly less likely to be adherent to (P < 0.001) and persistent with (P < 0.001) SGOAs, when compared with other racial groups. Approximately 97% of patients had mental-health substance coverage during the follow-up period. Higher percentage of adherent (70.8%) and persistent (69.4%) patients had fee-for-service health coverage compared with the non-adherent (65.8%) and non-persistent (66.7%) patients. Across both adherence and persistence groups over 96% of the patients had 'blind/disabled individual' listed as the reason for Medicaid eligibility. The adherent and persistent patients had significantly higher comorbidity burdens than non-adherent (P = 0.001) and nonpersistent (P = 0.011) patients.
Demographic characteristics
Unadjusted association between second-generation oral antipsychotics adherence and persistence and psychiatric-related relapses as well as schizophrenia-related and all-cause utilization Tables 4 and 5 summarize results from multivariable negative binomial and logistic regression analyses, respectively. The rate of psychiatric-related relapses was 10% lower among adherent than non-adherent patients (IRR: 0.90; 95% confidence interval (CI): 0.86-0.94; P < 0.001). Similarly, the rate of psychiatric-related relapse event was 12% lower among persistent than non-persistent patients (IRR: 0.88; 95% CI: 0.84-0.92; P < 0.001) ( Table 4) . Compared with nonpersistent patients, persistent patients had a significantly lower rate of schizophrenia-related inpatient admissions (IRR: 0.85; 95% CI: 0.77-0.93; P < 0.001). Compared with non-adherent and non-persistent patients, adherent (OR: 0.83; 95% CI: 0.71-0.96; P = 0.011) and persistent (OR: 0.76; 95% CI: 0.66-0.88; P < 0.001) patients had significantly lower likelihood of a schizophrenia-related inpatient admission during the postindex date period (Table 5 ). Compared with non-adherent and non-persistent patients, patients who were adherent (IRR: 0.79; 95% CI: 0.69-0.90; P < 0.001) and persistent (IRR: 0.81; 95% CI: 0.71-0.92; P < 0.001) had significantly lower rates of schizophrenia-related ED visits.
Schizophrenia patients adherent to SGOA therapy had higher rate of schizophrenia-related outpatient (IRR: 1.20; 95% CI: 1.00-1.43; P = 0.046) and physician office (IRR: 2.10; 95% CI: 1.70-2.58; P < 0.001) visits than the nonadherent patients. The rate of schizophrenia-related physician office visits was higher among persistent patients compared with the non-persistent (IRR: 1.89; 95% CI: 1.54-2.32; P < 0.001) patients. However, the rate schizophrenia-related outpatient visits did not differ significantly between the two persistence groups.
Persistent patients had a significantly lower rate of allcause inpatient admissions (IRR: 0.87; 95% CI: 0.82-0.93; P < 0.001) and ED visits (IRR: 0.78; 95% CI: 0.73-0.85; P < 0.001) compared with non-persistent patients. Compared with non-persistent patients, persistent patients had a significantly lower likelihood of all-cause inpatient admission during the 12-month postindex date period (OR: 0.77, 95% CI: 0.64-0.93; P = 0.007) patients. Similarly, the likelihood of an all-cause ER visit during the 12-month postindex date period was significantly lower among adherent (36%; OR: 0.64; 95% CI: 0.52-0.79; P < 0.001) and persistent (26%; OR: 0.74; 95% CI: 0.60-0.91; P = 0.005) patients compared with non-adherent and non-persistent patients respectively.
Finally, among patients adherent to and persistent with SGOA therapy, the rate of total medical encounters was higher, when compared with non-adherent (IRR: 1.65; 95% CI: 1.58-1.71; P < 0.001) and non-persistent (IRR: 1.55; 95% CI: 1.50-1.62; P < 0.001) patients (Table 4) .
Discussion
The extent of adherence to and persistence with SGOAs among Medicaid-enrolled schizophrenia patients experiencing Ն2 psychiatric-related relapses was examined. During the [27, 28] Approximately 50% of patients were persistent with SGOAs, 23% had Ն1 therapy interruption, and 27% discontinued their SGOAs.
The association between adherence to and persistence with SGOAs, psychiatric-related relapse rates, disease-specific and all-cause healthcare utilization during the postindex period was investigated. Both adherent and persistent patients had lower rates of psychiatric-related relapses. Compared with non-persistence with SGOAs, persistence resulted in a lower likelihood of both schizophrenia-related and all-cause inpatient and ED visits. These findings are consistent with other studies that have assessed the association between antipsychotic adherence and/or persistence and the risk of hospitalization. [9, 12, 28, 29] An example is Weiden et al., assessing association between partial compliance and risk of re-hospitalizations among schizophrenia patients enrolled in the California Medicaid programme. [9] The findings of this study indicate that a 30-day gap in antipsychotic medications significantly increased the risk of mental-health-related re-hospitalizations (OR: 2.81; 95% CI: 1.80-4.64) among patients with schizophrenia. [9] Similarly, another study conducted among Medicaid-enrolled schizophrenia patients reported that, compared with patients non-adherent to oral antipsychotic medications (cumulative possession ratio < 80%), adherent patients had a significantly lower rate of psychiatric-related hospitalization (34.9% versus 13.5%; P < 0.001). [28] Although our study focused on high-risk patients with schizophrenia experiencing multiple psychiatric-related relapses, the directionality of the association between adherence to and persistence with SGOAs and these events and inpatient and ED use is similar between this study and other published research. [9, 12, 28, 29] To address the issue of lower medication adherence, strategies such as patient education, pharmacist-based patient counselling, support of family and friends and improved access to care have been suggested as ways to improve therapy adherence among patients with chronic disorders, including schizophrenia. [7, [30] [31] [32] [33] [34] With respect to antipsychotic therapy, simplifying the therapy regimen by once-daily a Psychiatric-related relapse event rates and all-cause and schizophrenia-related healthcare utilization compared among patients adherent (MPR Ն 80%) and non-adherent (MPR < 80%) and persistent (continuous use defined as no refill gap or refill gap of Յ60 days for SGOA medication) and non-persistent (refill gap for SGOA medication > 60 days or SGOA discontinuation) with SGOAs. dosing, or by using long-acting injectable antipsychotic medications, may aid in improving adherence. [7, 30, 33, 35, 36] A recent study survey outlines expert consensus on issues associated with medication adherence among patients with serious mental-health disorders including schizophrenia. The survey findings indicate that physicians consider several advantages of long-acting injectables, including immediate recognition of non-adherence by the treatment prescriber, ease of use for the patient, lower risk of relapse. [33] Moreover, previous research suggests that schizophrenia patients had improved adherence to injectable antipsychotics compared with oral antipsychotics. [37] [38] [39] For example, the electronic Schizophrenia Treatment Adherence Registry was initiated to conduct international, prospective, observational studies comparing long-term outcomes among schizophrenia patients initiating oral antipsychotics or long-acting injectable risperidone. [39] The findings of this study indicate that among patients initiating long-acting injectable risperidone, the therapy retention rate was 81% at the end of the 2 year period compared with 63% for patients initiating oral antipsychotics. [39] Similarly, another retrospective chart study conducted among patients with schizophrenia reported decreased likelihood of hospitalization and shorter duration of hospitalization among longacting injectable risperidone users compared with oral antipsychotic users. [37] The current study was restricted to SGOAs; future research should focus on assessing therapy adherence, resource utilization and psychiatric-related relapses among patients with schizophrenia using injectable antipsychotic medications.
Finally, this study observed significantly higher schizophrenia-related hospital outpatient and physician office visits among adherent and persistent patients versus nonadherent and non-persistent patients. It is likely that the frequent physician-patient interactions are associated with improved SGOA adherence and persistence. Studies have reported that continuity of care and frequent patientphysician interactions are associated with improved therapy adherence and lower hospitalization rates. [40] [41] [42] This study is subject to limitations inherent in most retrospective claims data analyses. First, medication refill patterns in administrative data, while reflective of real-world prescription dispensing, may not reveal the true intent or directions of the prescribing physician. Failure to refill a prescription may occur for clinically appropriate reasons, such as medication AEs, adverse drug interactions, medication titration or abnormal laboratory results. [43] In administrative claims-based adherence studies, it is often assumed that medication refilled is medication consumed. However, patients may discard the medications before refill or may stockpile medication for future use. [43] These factors may cause the MPR to overestimate actual adherence. Even with these limitations, administrative claims data remain a reliable and well-accepted source for estimating adherence with chronic-use medications by using validated measures, such as the MPR. [8, 16, 24, 43] If ICD-9-CM diagnosis codes were recorded inaccurately, it may have resulted in some patients being misidentified as having schizophrenia. In order to lower the likelihood of misidentification of schizophrenia patients, this study required that the selected patients had Ն2 diagnosis claims for schizophrenia and had Ն1 claim for a schizophrenia-specific medication (an SGOA). Even with these precautions, the validity of our results depended on the accuracy of recordkeeping among providers submitting claims in the Medicaid database. No data on important clinical and demographic factors, including disease severity, medication AEs, or patient occupational status, education level and income were available; this may have an impact on medication adherence and resource utilization. The outcome measures considered for this included schizophrenia-related healthcare utilization and psychiatricrelated relapses. However, for the purposes of this study we did not assess costs associated with these outcomes measures. In future, additional research needs to be conducted to assess the costs savings resulting due to the lower rate of hospitalization and ED visits among patients adherent to SGAO therapy compared with non-adherent patients. Also, we did not estimate indirect cost savings that could be attributed to a lower rate of psychiatric relapse, such as increased likelihood of employability, [44] savings in informal care-giving time and better transition to the community. [45, 46] Finally, this analysis was limited to US Medicaid enrollees; therefore, these findings may not be generalizable to individuals enrolled in other federal or commercial health plans or to individuals without health coverage.
Conclusions
This study reinforces the need among patients with schizophrenia for improved treatment adherence and persistence, which may help lower the rate of psychiatric-related relapse. Prior research suggests that Medicaid is the largest payer of mental-health care in the USA, with schizophrenia being the primary cost driver of mental-health care. [21, 47, 48] Given the declining Medicaid funding, states are likely to adopt costcutting measures that may affect medical care access to the vulnerable mental-health population. [49] Thus, interventions that may aid in lowering the rate of psychiatric-related relapse among Medicaid-enrolled patients with schizophrenia may help lower the direct economic burden exerted by this population on the Medicaid system.
One of the interventions to lower the psychiatric-relapse rate would be to improve adherence and persistence to the prescribed therapy among schizophrenia patients. However, despite publication of numerous studies outlining the association between lower therapy adherence and increased risk of hospitalization, improving adherence and persistence among patients with schizophrenia remains a significant challenge to healthcare providers. [11, 12, 28, 50] Nonetheless, interventions aimed at improving antipsychotic therapy adherence, such as pharmacist-based patient counselling, simplifying dosing regimen and use of once-a-day medications or long-acting injectables, may aid in improving therapy adherence among high-risk patients with schizophrenia experiencing multiple psychiatric-related relapses.
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